Desmoplastic stromal compositions are known to be associated with poor patient outcome e.g. in pancreatic cancer independent of anti-angiogenic therapy (95), it is therefore particular detrimental that VEGF inhibition might even exacerbate this situation and potentially contributes to primary resistance of anti-angiogenic drugs in several cancer entities. This evidence concerns the gene VEGFA and cancer.